Vivus’s Qnexa, the first of three new anti-obesity drugs under FDA review this year, came before one of the agency’s advisory committees today — and it was a swing and a miss. The panel recommended against …
VIVUS, Inc. (NASDAQ:VVUS) shares soared 11% to $20.58 after Bloomberg Industries claims the prescription insurer …
If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com Cambridge, …